Clinical effects of raloxifene hydrochloride in women

Annals of Internal Medicine

Volumn 130, Issue 5, 1999, Pages 431-439

  Khovidhunkit, Weerapan ^a   Shoback, Dolores M ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

BONE DENSITY; BONE MINERAL; BREAST CANCER; CARDIOVASCULAR DISEASE; COGNITION; DRUG EFFECT; DRUG MECHANISM; FEMALE; FRACTURE; HOT FLUSH; HUMAN; LIGAND BINDING; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; UTERUS CANCER;

EID: 0033515045     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-5-199903020-00015     Document Type: Review

References (86)

1. Grodstein F, Stampfer MJ, Coldite GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-75.
2. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-62.
3. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
4. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteo-porotic Fractures Research Group. Ann Intern Med. 1995;122:9-16.
5. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cam Memorial Award Lecture. Cancer Res. 1990;50:4177-89.
6. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:71-85.
7. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-6.
8. Grey AB, Stapleton JP, Evans MC, Reid IR. The effects of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191-5.
9. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-52.
10. Black LJ, Jones CD, Clark JH, Clemens JA. LY 156758 a unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity and near-total estrogen antagonism in vivo [Abstract]. Breast Cancer Res Treat. 1982;2:279.
11. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983;32:1031-6.
12. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo [b]thiophene derivatives leading to [6-hydroxy-2-(4-h/droxyphenyl)benzo[b] thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkable effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem. 1984;27:1057-66.
13. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new estrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 1983;32:2869-75
14. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antiestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem. 1984;20:111-20.
15. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988;48:6764-8.
16. Jordan VC, Phelps E, Undgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 1987;10:31-5.
17. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;9363-9.
18. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-7.
19. Baker VL, Jaffe RB. Clinical uses of antiestrogens. Obstet Gynecol Surv. 1996;51:45-59.
20. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 1997;48:155-63.
21. Riggs BL. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women [Editorial]. J Clin Endocrinol Metab. 1996,81:2417-8.
22. Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CW, et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem. 1997;40:146-67.
23. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators Proc Natl Acad Sci U S A. 1997;94:14105-10.
24. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog. 1996;17:151-9.
25. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell. 1990;63:1267-76.
26. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 1995;9:443-56.
27. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones Mol Endocrinol. 1996;10:119-31.
28. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 1995;9:659-69.
29. Brzozowski AM, Pike AC, Darter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753-8.
30. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 1996;273:1222-5.
31. Cheskis BJ, Karathanasis S, Lyttle CR. Estrogen receptor ligands modulate its interaction with DNA. J Biol Chem. 1997;272:11384-91.
32. Elgort MG, Zou A, Marschke KB, Allegretto EA. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α1 promoter via a novel sequence Mol Endocrinol. 1996;10:477-87.
33. Halachmi S, Marden E, Martin G, Mackay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 1994;264:1455-8
34. Weiss DJ, Gurpide E. Non-genomic effects of estrogens and antiestrogens. J Steroid Biochem. 1988,31:671-6.
35. Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens Breast Cancer Res Treat. 1994;31:5-9.
36. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925-30.
37. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
38. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and β. Endocrinology, 1997;138:863-70.
39. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, et al. Differential expression of estrogen receptors a and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology. 1997;138:5067-70.
40. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast tumors J Clin Endocrinol Metab. 1996;82: 2371-4
41. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J Comp Neurol. 1997;388:507-25.
42. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997;277:1508-10.
43. Frolik CA, Black LJ, Osborne JJ, Rowley ER, Kau DL, Occolowitz JL. In vivo and in vilto metabolism of raloxifene [Abstract]. J Bone Miner Res. 1993; 8(Suppl 1):S282.
44. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, et al. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol. 1997;61:97-106.
45. Khovidhunkit W, Epstein S. Cytokines and osteoporosis. In: LeRoith D, Bondy C, eds. Growth Factors and Cytokines in Health and Disease: A Multi-Volume Treatise. v. 3B. Greenwich, CT: JAI Pr; 1997:459-97.
46. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, et al. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 1996;137:2075-84.
47. Glasebrook AL, Short LL, Cole HW, Magee DE, Bryant HU. Regulation of serum IL-6 by raloxifene in an ovariectomized rat model [Abstract]. Bone. 1995;16(Suppl 1):99S.
48. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone. 1996;18:621-7.
49. Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, et al. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res. 1994;9:715-24.
50. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovanectomized rats. Endocrinology 1994;135:2001-5.
51. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther. 1995;272:1252-9.
52. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996,10:905-12.
53. Evans GL, Bryant HU, Magee DE, Turner RT. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology. 1996;137:4139-44
54. Hock JM, Cain R, Hulman J. Combination of raloxifene and human parathyroid hormone 1-34 increase femur bone mass in young ovariectomized (OVX) rats [Abstract]. J Bone Miner Res. 1993;8(Suppl 1):S157.
55. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-8
56. Sato M, Bryant HU, Iversen P. Helterbrand J, Smietana F, Bemis K, et al. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther. 1996;279:298-305.
57. Ettinger B, Black D, Cummings S, Genant H, Gluer C, Lips P, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses [Abstract]. Osteoporosis Int. 1998;8(Suppl 3):11.
58. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-42.
59. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab. 1997;82:3425-9.
60. Ma PT, Yamamoto T, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17α-ethinyl estradiol. Proc Natl Acad Sci U S A. 1986;83:792-6.
61. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther. 1997;280:146-53.
62. Lundeen SG, Carver JM, McKean ML, Winneker RC. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology. 1997;138:1552-8.
63. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996;126:65-75.
64. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 1997;96:1964-9.
65. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998;83:721-6.
66. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-51.
67. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs. 1994;47(Suppl 2):35-41.
68. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47:4020-4.
69. Poulin R, Merand Y, Poirier D, Levesque C, Dufour JM, Labrie F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICl 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 1989;14:65-76.
70. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344-5.
71. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl. 1995;22:51-7.
72. Ziegler J. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study. J Natl Cancer Inst. 1996;88:1100-2.
73. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid J Natl Cancer Inst. 1996;88:123-5.
74. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometnal cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial [Abstract]. Proceedings of the American Society of Clinical Oncology Meeting. 1998:3.
75. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa T, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in -12,000 postmenopausal women [Abstract]. Proceedings of the American Society of Clinical Oncology Meeting. 1998:466.
76. Somjen D, Waisman A. Kaye AM. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J Steroid Biochem Mol Biol. 1996;59:389-96.
77. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometnal carcinoma (EnCa101) in athymic mice. Cancer Res. 1990;50:3189-92
78. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458-64.
79. Baker VL, Draper M, Paul S, Allerheiligen S, Giant M, Shifren J, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 1998;83:6-13.
80. Kessel B, Hsueh AJ. Keoxifene (LY 156758) inhibits follicle-stimulating hormone induced differentiation of cultured rat granulosa cells. Life Sci. 1987; 40:1089-97.
81. Evista (raloxifene) tablets product monograph [Package insert]. Indianapolis: Eli Lilly & Co.; 1997.
82. Simard J, Labrie F. Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol. 1985;39:141-4.
83. Ortmann O, Emons G, Knuppen R, Catt KJ. Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary goradotrophs. Endocrinology. 1988;123:962-8.
84. Petersen SL, Barradough CA. Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain. Brain Res. 1989;484:279-89.
85. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Antiestrogenic properties of raloxifene. Pharmacology. 1995;50:209-17.
86. Delmas PD, Mitlak BH, Christiansen C. Effects of raloxifene in postmenopausal women [Letter] N Engl J Med. 1998;338:1313-4.